PMID

Data

Article Title

Organization

Discovery of Potent, Orally Bioavailable Inhibitors of Human Cytomegalovirus.

Boehringer Ingelheim (Canada)

Multi-parameter optimization of aza-follow-ups to BI 207524, a thumb pocket 1 HCV NS5B polymerase inhibitor. Part 2: Impact of lipophilicity on promiscuity and in vivo toxicity.

Boehringer Ingelheim (Canada)

Discovery of BI 207524, an indole diamide NS5B thumb pocket 1 inhibitor with improved potency for the potential treatment of chronic hepatitis C virus infection.

Boehringer Ingelheim (Canada)

Minimizing the Contribution of Enterohepatic Recirculation to Clearance in Rat for the NCINI Class of Inhibitors of HIV.

Boehringer Ingelheim (Canada)

Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1.

Boehringer Ingelheim (Canada)

Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: discovery of a quinazolinone chemotype.

Boehringer Ingelheim (Canada)

Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus.

Boehringer Ingelheim (Canada)

Discovery of a novel series of non-nucleoside thumb pocket 2 HCV NS5B polymerase inhibitors.

Boehringer Ingelheim (Canada)

Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV).

Boehringer Ingelheim (Canada)

Nonpeptidic, monocharged, cell permeable ligands for the p56lck SH2 domain.

Boehringer Ingelheim (Canada)

Peptide-based inhibitors of the hepatitis C virus serine protease.

Boehringer Ingelheim (Canada)

From benzimidazole to indole-5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase. Part 1: indole C-2 SAR and discovery of diamide derivatives with nanomolar potency in cell-based subgenomic replicons.

Boehringer Ingelheim (Canada)

Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.

Boehringer Ingelheim (Canada)

Benzimidazole Thumb Pocket I finger-loop inhibitors of HCV NS5B polymerase: improved drug-like properties through C-2 SAR in three sub-series.

Boehringer Ingelheim (Canada)

Discovery of benzimidazole-diamide finger loop (Thumb Pocket I) allosteric inhibitors of HCV NS5B polymerase: Implementing parallel synthesis for rapid linker optimization.

Boehringer Ingelheim (Canada)

Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors.

Boehringer Ingelheim (Canada)

A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease: discovery of potent and specific tripeptide inhibitors.

Boehringer Ingelheim (Canada)

Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency.

Boehringer Ingelheim (Canada)

NMR structural characterization of peptide inhibitors bound to the Hepatitis C virus NS3 protease: design of a new P2 substituent.

Boehringer Ingelheim (Canada)

Discovery of small-molecule inhibitors of the ATPase activity of human papillomavirus E1 helicase.

Boehringer Ingelheim (Canada)

Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery and preliminary SAR of benzimidazole derivatives.

Boehringer Ingelheim (Canada)

Aligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs.

Boehringer Ingelheim (Canada)

Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease.

Boehringer Ingelheim (Canada)

Inhibition of human cytomegalovirus protease N(o) with monocyclic beta-lactams.

Boehringer Ingelheim (Canada)

beta-Lactam derivatives as inhibitors of human cytomegalovirus protease.

Boehringer Ingelheim (Canada)

Identification of potent and orally bioavailable nucleotide competing reverse transcriptase inhibitors: in vitro and in vivo optimization of a series of benzofurano[3,2-d]pyrimidin-2-one derived inhibitors.

Boehringer Ingelheim (Canada)

Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 1: addressing configurational instability through scaffold modification.

Boehringer Ingelheim (Canada)

Inhibition of HIV-1 capsid assembly: optimization of the antiviral potency by site selective modifications at N1, C2 and C16 of a 5-(5-furan-2-yl-pyrazol-1-yl)-1H-benzimidazole scaffold.

Boehringer Ingelheim (Canada)

Thiotetrazole alkynylacetanilides as potent and bioavailable non-nucleoside inhibitors of the HIV-1 wild type and K103N/Y181C double mutant reverse transcriptases.

Boehringer Ingelheim (Canada)

Heterocyclic compounds and methods for their use

Novartis

C5-C6-oxacyclic fused iminopyrimidinone compounds as bace inhibitors, compositions, and their use

Merck Sharp & Dohme

Oxindole compounds carrying a nitrogen-bound spiro substituent and use thereof for treating vasopressin-related diseases

Abbvie Deutschland

Synthesis of substituted diarylmethylenepiperidines (DAMPs), a novel class of anti-HIV agents.

Purdue University